Chemically Reprogrammed Retinal Ganglion Cell Therapy to Treat Glaucomatous Neuropathy (for Dr. Mahato)

StatusActive
Effective start/end date1/03/1929/02/20

Funding

  • Glaucoma Research Foundation: $50,000.00

Keywords

  • Neurosciences, Vision Research